The topic of HYDIA is one that has generated great interest over time. With diverse edges and approaches, HYDIA has captured the attention of experts and fans alike. In this article, we will explore different aspects related to HYDIA, from its origin to its implications in today's society. Through a detailed and exhaustive analysis, we will seek to better understand HYDIA and its relevance in the current context. From its origins to its impact today, HYDIA has been the subject of debate and reflection, and through this article, we will seek to shed light on its key points.
HYDIA is a drug that is used in neuroscience research, which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3). It has been useful in the mapping of the group II mGluR receptor proteins and their molecular modeling.[1] HYDIA is similar in structure to group II mGluR agonists such as eglumetad and pomaglumetad, but the addition of the 3-hydroxy group reverses the activity to a competitive antagonist. Other derivatives such as the 3-benzyloxy ether are more potent antagonists than HYDIA itself.[2]
References
^Lundström L, Kuhn B, Beck J, Borroni E, Wettstein JG, Woltering TJ, Gatti S (July 2009). "Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA". ChemMedChem. 4 (7): 1086–94. doi:10.1002/cmdc.200900028. PMID19402024. S2CID9062937.
^Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F (February 2008). "Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclohexane-2,6-dicarboxylic acid-HYDIA". ChemMedChem. 3 (2): 323–35. doi:10.1002/cmdc.200700226. PMID18058780. S2CID1695024.